Blog
Key Takeaways from the 2025 ixlayer Client Advisory Meeting
In Case You Missed It: Key Takeaways from the 2025 ixlayer Client Advisory Meeting In early March, ixlayer hosted an
April 29, 2025
ixlayer’s unified direct-to-patient platform, helps biopharma transform the patient experience
Simplify and Accelerate the Connection to Care
Scheduled a visit with a
physician after receiving
abnormal lab results.
Patient activation increase
vs. traditional outreach.
Increase in diagnostic testing compliance vs. U.S benchmark.
Intuitive interface and simple one-time sign-on supports continuous patient engagement
Connection to PCPs and Specialists virtually and in-person accelerates the connection to care
Deep partnerships across the healthcare ecosystem support multiple, differentiated patient journeys
Proactive care and convenient health access drive earlier interventions and help patients achieve their health goals
ixlayer connects a vast health ecosystem for a convenient and seamless virtual patient experience. Users can screen for health conditions, easily monitor their health, seamlessly connect with care providers and have medication delivered all without leaving our platform.
Seamlessly integrate with a vast health ecosystem and launch services to support specific brand initiatives.
Built on a secure technological backbone, our flexible product design enables rapid deployment and scalability, and allows us to configure solutions to best meet our clients’ needs across multiple therapeutic areas.
Telehealth services, lab testing, Rx fulfillment, benefits verification, and more can be implemented across a patient journey designed to support different patient needs and priorities.
We offer our clients the opportunity to deliver a personalized healthcare journey to all patients with our fully integrated, configurable platform. We have powered over 1,100 nationwide programs and enabled over 4 million patient care journeys for greater operational efficiency, patient access, and improved outcomes.
Across the biopharma industry,
our clients value our speed, our service and our solutions.
The latest research, news and expert opinion keeping you up to date on DTP industry innovation.
This article was originally published in Pharmaceutical Executive. Engaging Patients: Why Pharma’s Direct-to-Patient Approach Should Be Applauded Physicians remain central
New remote options for Complete Blood Count tests pave the way for more cost-effective, patient-focused care New remote options for
Fierce Pharma publisher Rebecca Willumson caught up with ixlayer’s General Manager of Biopharma, Matthew Walsh, at Digital Pharma East 2024
3 Takeaways for Pharma Marketers from Our Discussion with Jessica Greig at Digital Pharma East 2024 3 minute read At
In Case You Missed It: Key Takeaways from the 2025 ixlayer Client Advisory Meeting In early March, ixlayer hosted an
Pharma’s Role in Improving the Health Experience: Understanding Patient Expectations Patients have become accustomed to digital health, but they struggle
ixlayer and Ipsos’ “ixInsights 2025” Study Reveals Consumer Expectations for Digital Health and Pharma’s Role in Enhancing Patient Experience Study
IX Layer Inc.
447 Sutter Street, Suite 405, PMB 53
San Francisco, CA 94108
IX Layer Inc.
222 Broadway, 22nd Floor
New York, NY 10038